Navigation Links
Spectral to bring anti-sepsis therapy to the U.S. market
Date:9/23/2008

TORONTO, Sept. 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that it has agreed to key terms with Toray Industries Inc. of Japan to obtain the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream. Under the terms of the agreement, the Company will seek FDA approval for a combined product for the treatment of severe sepsis that will include Toraymyxin(TM) and Spectral's Endotoxin Activity Assay (EAA(TM)), the only FDA cleared diagnostic for the measurement of endotoxin. The conclusion of final commercial agreements is subject only to the completion of due diligence by Spectral and the determination of an approved clinical development pathway with the U.S. FDA.

"Toraymyxin(TM) is marketed in Japan and Europe and has been used to treat more than 50,000 sepsis patients safely and effectively. Spectral's EAA (TM) can identify patients that will benefit from Toraymyxin(TM) and monitor the effects of the treatment," said Dr. Paul Walker, President and CEO of Spectral. "This combination of the EAA(TM) diagnostic and the Toraymyxin(TM) therapeutic has been utilized by clinicians in Europe since November 2007 and has demonstrated the potential to lead to a significant reduction in mortality, as documented in the findings presented at the 28th International Symposium on Intensive Care and Emergency Medicine in March 2008. We believe that this combined treatment can fulfill a major unmet need for the approximately 100,000 patients that develop severe sepsis or septic shock in the U.S. each year."

"The business alliance with Toray and the specific combination of our approved diagnostic with their therapeutic device represent a significant market opportunity for Spectral," said Anthony Businskas, Spectral's Executive Vice-President and CFO. "Over the coming months, we expect to complete our due diligence and discuss the clinical development pathway for this combined product with the U.S. FDA. Finalization of the exclusive license and material supply agreements with Toray is anticipated to occur in the first quarter of 2009."

About Toray

Toray Industries, Inc. is a leading diversified chemicals corporate group that has been technology-focused since its foundation in 1926. The company's operations are underpinned by technological expertise in organic synthetic chemistry, polymer chemistry, and biochemistry. These innovative technologies have yielded "advanced materials" that Toray is now exploiting to provide customers with comprehensive solutions through Fibers and Textiles, Plastics and Chemicals, IT-related Products, Carbon Fiber Composite Materials, Environment and Engineering, Life Science and Other Business divisions. In FY2008, Toray had consolidated sales of 1,650 billion yen (approx $15 billion US), and over 33,000 employees worldwide. For further information, please check http://www.toray.co.jp.

About Spectral Diagnostics

Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed for this indication, Spectral is well-positioned to drive the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
2. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
3. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
4. Spectral and Toray expand collaboration to include new geographic territories
5. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
6. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
7. Spectral announces 2007 financial results
8. Spectral appoints Anthony Bihl to Board of Directors
9. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
10. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
11. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):